IQVIA HOLDINGS INC. Annual Report - A Deeper Dive for Investors

IQVIA Holdings Inc. delivered a strong performance in fiscal year 2025. This summary unpacks the company's results, offering a comprehensive view of this healthcare and life sciences data, technology, and research leader.

Business Overview

IQVIA Holdings Inc. stands as a global leader, providing advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company operates at the intersection of healthcare and technology, leveraging its vast data assets, proprietary technologies, and deep industry expertise. IQVIA helps pharmaceutical, biotechnology, medical device, and other healthcare companies develop and commercialize their products more efficiently and effectively. Its comprehensive offerings span clinical development, commercialization, and real-world evidence generation, supporting clients from drug discovery to patient care.

Financial Highlights: Steady Growth, Profitability, and Cash Flow

IQVIA demonstrated consistent financial performance in 2025, achieving solid revenue growth and healthy profitability despite rising operational costs.

• Total Revenue: The company's total revenue grew 5.35% to $18.93 billion in 2025, up from $17.97 billion in 2024. This continues a strong upward trend from $17.04 billion in 2023, showcasing sustained demand for IQVIA's services.
• Operating Income (Adjusted EBITDA): IQVIA's Adjusted EBITDA, a key measure of core operational profitability, reached $4.1 billion in 2025. This represents a 6.5% increase from $3.85 billion in 2024, indicating efficient management of core operations that outpaced revenue growth.
• Net Income: IQVIA reported a Net Income of $1.65 billion in 2025, an increase of 7.8% from $1.53 billion in 2024. This translated to Diluted Earnings Per Share (EPS) of $8.80 in 2025, compared to $8.10 in 2024, reflecting improved shareholder value.
• Cash Flow from Operations: The company generated substantial operating cash flow, reaching $2.7 billion in 2025, up from $2.5 billion in 2024. This strong cash generation provides crucial liquidity for investments, debt servicing, and shareholder returns.

Segment Performance: Broad-Based Strength

All three of IQVIA's core segments contributed positively to the year's growth, demonstrating diversified strength across its offerings.

• Research & Development Solutions: As IQVIA's largest segment, it grew to $11.9 billion in 2025, a 5.3% increase from $11.3 billion in 2024. Increased demand for clinical trial services and outsourced R&D, reflecting a healthy pharmaceutical industry pipeline, primarily drove this growth.
• Technology & Analytics Solutions: This segment, which provides critical data and technology tools, reached $6.43 billion in 2025, up 5.4% from $6.1 billion in 2024. Expansion in real-world evidence solutions and AI-powered analytics platforms were key drivers.
• Contract Sales & Medical Solutions: This smaller segment, focusing on sales and medical services, grew to $600 million in 2025, a 5.3% increase from $570 million in 2024. New client engagements and expanded service offerings supported this growth.

Geographic Footprint: Global Reach with U.S. Dominance

The United States remains IQVIA's largest market, but international contributions also play a significant role.

• U.S. Revenue: Sales in the U.S. alone hit $7.9 billion in 2025, up 5.3% from $7.5 billion in 2024. This mirrors the overall company growth rate and underscores the stability of IQVIA's domestic operations.
• International Revenue: International markets collectively contributed approximately $11.03 billion in 2025, growing at a similar pace to the U.S. This global presence diversifies revenue streams and reduces reliance on any single region.

Cost Structure and Efficiency: Managing Growth

While revenue grew, the company also saw an increase in operational expenses.

• Selling, General & Administrative (SG&A) Expenses: These costs, covering marketing, sales, and administrative functions, increased to $2.7 billion in 2025, an 8% jump from $2.5 billion in 2024. This higher growth rate compared to revenue primarily resulted from increased investments in sales force expansion, technology infrastructure, and integration costs from recent acquisitions.
• Depreciation, Amortization & Interest: These non-operating costs rose to $2.5 billion in 2025, up 4.17% from $2.4 billion in 2024. The slower growth rate relative to revenue indicates efficient capital management and a stable cost of debt.

Capital Allocation: Returning Value and Strategic Investments

IQVIA continued its commitment to shareholder returns and strategic growth through acquisitions.

• Share Repurchases: The company bought back $1 billion worth of its own shares in 2025, consistent with prior years. This strategy aims to enhance shareholder value by reducing the number of outstanding shares and boosting EPS.
• Acquisitions: IQVIA executed a "series of individually immaterial business acquisitions" in both 2024 and 2025, totaling approximately $500 million in cash outflow for these strategic investments. These acquisitions typically focus on expanding IQVIA's data assets, technology capabilities, or specialized service offerings, reinforcing its market leadership.

Financial Health and Key Considerations for Investors

Understanding IQVIA's financial position, particularly its debt and future obligations, is crucial for investors.

• Debt Profile: IQVIA carries a significant amount of debt, totaling approximately $13.5 billion in long-term debt as of year-end 2025. This includes various senior secured notes and term loans. While the debt structure is diversified and includes access to a $2 billion revolving credit facility and a $1 billion accounts receivable financing facility for liquidity, investors should monitor the company's debt-to-EBITDA ratio, which stood at approximately 3.3x in 2025.
• Contingent Consideration: This liability, representing potential future payments related to past acquisitions, grew to $1.1 billion in 2025, a 10% increase from $1 billion in 2024. This indicates continued M&A activity and potential future cash outflows, which could impact future earnings if performance targets are met.
• Liquidity: With cash and cash equivalents of approximately $1.2 billion at year-end 2025 and strong operating cash flow, IQVIA maintains adequate liquidity to meet its short-term obligations.

Future Outlook and Strategic Focus

IQVIA's strategy centers on leveraging its integrated data, technology, and services to drive innovation in the life sciences industry. Key strategic pillars include:

• Data & AI Leadership: Continuing to invest in advanced analytics, artificial intelligence, and real-world data to provide deeper insights for clients.
• Global Expansion: Strengthening its presence in emerging markets and expanding service offerings internationally.
• M&A Integration: Successfully integrating acquired companies to enhance capabilities and achieve synergies.
• Operational Efficiency: Optimizing cost structures while investing in growth initiatives.

For the upcoming fiscal year 2026, management projects continued revenue growth in the range of 5-7% and Adjusted EPS growth of 9-11%, reflecting confidence in IQVIA's market position and strategic initiatives.

Competitive Position

IQVIA operates in highly competitive markets characterized by rapid technological change and evolving client needs. The company's competitive advantages stem from its unique combination of proprietary data, advanced analytics capabilities, integrated technology platforms, and global clinical research services. Its extensive real-world data assets, coupled with AI-powered analytics, differentiate its offerings. Competitors include other contract research organizations (CROs), healthcare technology providers, data analytics firms, and consulting companies. IQVIA maintains its market leadership through continuous innovation, strategic acquisitions, and the ability to offer end-to-end solutions that address complex client challenges across the entire life sciences value chain.

Key Risks to Monitor

Investors should be aware of several potential risks:

• High Debt Levels: While manageable, significant debt could limit financial flexibility or increase interest expenses in a rising interest rate environment.
• Acquisition Integration Risk: The company's active M&A strategy carries risks related to successfully integrating new businesses and realizing expected synergies.
• Regulatory and Data Privacy: Operating in a highly regulated healthcare industry, changes in data privacy laws or healthcare regulations could impact operations and compliance costs.
• Competition: The market for healthcare data, technology, and R&D services is competitive, requiring continuous innovation.
• Economic Downturns: A global economic slowdown could impact R&D spending by pharmaceutical and life sciences companies.

The Bottom Line for Investors

IQVIA delivered a strong financial performance in 2025, marked by consistent revenue and profit growth across all segments. The company effectively generates cash, actively returns value to shareholders through buybacks, and strategically invests in growth through acquisitions. While its significant debt and growing contingent consideration warrant attention, IQVIA's robust market position, diversified offerings, and positive outlook suggest it remains a compelling investment in the vital healthcare and life sciences sector.